With the aim to build a therapeutic platform against T-ALL, we developed a novel asy metric BTCE that simultaneously binds a unique epitope of CD1a and CD3ε (CD1a x CD3ε) to recruit and trigger a powerful T-cell-mediated anti-tumor response. Here, CD1A is linked to acute lymphoblastic leukemia.